CN110407937A - 一种抗amh单克隆抗体的制备及其应用 - Google Patents

一种抗amh单克隆抗体的制备及其应用 Download PDF

Info

Publication number
CN110407937A
CN110407937A CN201810382246.8A CN201810382246A CN110407937A CN 110407937 A CN110407937 A CN 110407937A CN 201810382246 A CN201810382246 A CN 201810382246A CN 110407937 A CN110407937 A CN 110407937A
Authority
CN
China
Prior art keywords
amh
ser
leu
antibody
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810382246.8A
Other languages
English (en)
Inventor
李思慧
魏赵延
林伟强
吴凯
朱庆平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Zhengda Tianchuang Biological Engineering Co Ltd
Original Assignee
Jiangsu Zhengda Tianchuang Biological Engineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Zhengda Tianchuang Biological Engineering Co Ltd filed Critical Jiangsu Zhengda Tianchuang Biological Engineering Co Ltd
Priority to CN201810382246.8A priority Critical patent/CN110407937A/zh
Publication of CN110407937A publication Critical patent/CN110407937A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及抗人AMH抗体及其应用。本发明制备了多种抗体,并进行配对筛选,获得灵敏度及特异性均能满足需求的抗体组合。

Description

一种抗AMH单克隆抗体的制备及其应用
技术领域
本发明涉及生物技术领域,尤其涉及两种分泌可配对的抗AMH单克隆抗体的杂交瘤细胞株及其单抗的应用。
背景技术
抗穆勒氏管激素(anti-Mullerian hormone,AMH)是转化生长因子β 超家族的成员之一,由Professor Alfred Jost于1974年首先发现。AMH是由两个相同的70KD亚基,通过二硫键连接组成的二聚糖蛋白,相对分子质量为140KD;人类AMH编码基因位于19号染色体短臂,大小2.4~2.8kb,含有5个外显子。
抗穆勒氏管激素(AMH)在性腺器官发育过程中起着重要作用,是男女性腺功能的重要标记物之一。在男性AMH主要由睾丸间质细胞产生,始于胚胎形成并贯穿生命始终;在男性胎儿的发育过程中,AMH导致穆勒氏管退化,形成正常发育的男性生殖管道。在女性AMH主要由卵巢颗粒细胞产生,血清AMH保持相对于男性较低的一个水平,从青春期开始,血清AMH水平随时间慢慢降低,并在更年期降低到ELISA法检测不到的水平。
AMH的正常值界于2-6.8ng/ml之间,AMH数值越高,代表卵子存量越丰沛,适合受孕的黄金期较长,AMH值越低则卵巢功能越差,35岁过后AMH值会开始急剧下降,当AMH值低于0.7ng/ml时,表示卵子库存量已严重不足,几乎难以受孕。若AMH值大于6.8时,可考虑有多囊性卵巢症候群的体质,使用排卵针剂、药物时,卵巢也容易对反应过度而排出过多的卵子,造成卵巢过度刺激症候群。
发明内容
本发明的目的是提供单克隆抗体AMH-1和AMH-2。其中单克隆抗体AMH-1的重链可变区的核苷酸序列如SEQ ID NO:XX所示,轻链可变区的核苷酸序列如SEQ ID NO:XX所示;单抗AMH-2重链可变区和轻链可变区的核苷酸序列分别如SEQ ID NO:XX和SEQ ID NO:XX所示。
本发明还提供上述抗AMH单抗的应用。利用抗体AMH-1作为包被抗体,AMH-2作为标记抗体,建立了DAS-ELISA方法,以检测天然血清中的AMH。
附图说明
图1是单克隆抗体的配对筛选结果;
图2是抗体AMH-1、AMH-2的分型鉴定结果。
图3是使用抗体分型鉴定试剂盒SBA Clonotyping System-HRP(SouthernBiotech, cat: 5300-05),ELISA检测OD450计数结果。
图4使用抗体分型鉴定试剂盒SBA Clonotyping System-HRP(Southern Biotech,cat: 5300-05),按说明书方法进行鉴定结果。
具体实施方式
下面结合实施例和附图对本发明作进一步说明。
一、杂交瘤细胞的获得及其单克隆抗体的制备
1. 动物免疫
免疫原为大肠杆菌重组表达蛋白(59KD),编码序列为NP_000470(Arg26 – Arg560),购自北京爱必信生物科技有限公司,货号为TP710250。用此重组蛋白免疫6周龄体重18-20 g的 BALB/c雌性小鼠。即AMH重组蛋白100 µg/只与福氏完全佐剂混合,充分乳化后,经背腹部皮下多点注射0.3 mL/只,后每间隔2周,取80 µg/只抗原和福氏不完全佐剂充分乳化后,腹腔注射0.3 mL/只,免疫第4次的一周后,对小鼠进行眼球取血,检测血清效价,取效价达到1:105及以上的小鼠进行脾脏加强免疫,脾脏免疫时,重组抗原量为30ug/只,3天后取脾细胞进行细胞融合。
2. 饲养层细胞的制备
取BALB/c小鼠腹腔巨噬细胞和胸腺细胞作为饲养细胞,具体操作方法如下:取BALB/c小鼠,眼球放血致死,75%酒精体表消毒后,用消毒后的剪刀和镊子从后腹剪开腹部皮肤,暴露腹膜。用注射器取4 ml IMDM培养基至腹腔,用手指轻轻挤压腹部,并进行反复冲洗,回收冲洗液。取出小鼠的胸腺,将其碾碎后用IMDM培养基冲洗,回收洗液。将两次回收液混合后,1200 rpm/min 离心3min,弃上清,即得到饲养层细胞。
3. 细胞融合
取免疫小鼠脾细胞与小鼠骨髓瘤细胞 (SP2/0) 按7:1的比例在无血清的IMDM 培养基中混匀,1,300 rpm离心3 min,去除培养基,在37 ℃水浴中加入1 mL 50 % PEG (分子量1500)并融合2 min,用无血清的IMDM培养基终止融合后1,300 rpm离心3 min,沉淀用HAT培养基悬浮,并加入饲养层细胞,分装到96孔含有饲养细胞的细胞板中,并置于37 ℃,含5 %CO2的细胞培养箱中培养。
4. 杂交瘤细胞的筛选及其克隆
细胞培养箱中培养5天后,等到融合细胞覆盖孔底10-30 %时,用常规间接ELISA方法筛选分泌抗体的阳性孔,即以AMH重组蛋白为抗原,用CB稀释到0.5μg/ml包被96孔酶标板,50ul/孔,4℃包被过夜,拍干后,用含1% BSA的PBS缓冲液封闭(200 ul/孔),37℃封闭2小时,拍干备用;将待检细胞培养上清50 ul/孔加入上述ELISA板中,于37℃反应30min后洗涤并拍干,加入50 ul/孔的HRP标记的羊抗鼠IgG,于37℃孵育30min后洗涤并拍干,加入50 ul/孔的TMB显色液,于37℃避光显色10 min,加入25 ul/孔的2 M H2SO4终止反应,并于0D450处读取数值。阳性孔的确定原则:OD450值/阴性对照值≥2.1。选择呈强阳性反应的细胞孔,进行有限稀释法克隆。经过三至四次的克隆化筛选后,单克隆细胞株阳性率100%即确定为稳定细胞株。经扩大培养后,用于腹水制备和液氮保存。
5. 单克隆抗体腹水制备及纯化
取8周龄左右F1小鼠,腹腔注射0.3-0.5 mL石蜡,7-10天后腹腔注入8×105个杂交瘤细胞,注射后7-10天可见小鼠腹部明显膨大,注射针头采取腹水,8,000 rpm离心3 min,收集上清液即为单抗腹水。取1倍体积腹水加2倍体积0.06 M pH 4.8醋酸缓冲液稀释,室温下边搅拌边加辛酸 (30 uL/mL腹水),4 ℃澄清1 h,12,000 rpm离心20 min,收集上清,再用50%饱和硫酸铵沉淀免疫球蛋白,4℃放置2 h,3,000 rpm离心20 min,沉淀用2倍体积的PBS溶液溶解,在4 ℃流动透析24 h后即获纯化的腹水抗体,-70 ℃保存。
二、配对抗体的筛选制备
1. 抗体的HRP标记
取1mg HRP溶于0.5ml的蒸馏水中,再加入0.2ml NaIO4溶液(0.06mol/L),混匀后置于4℃避光条件下30min。加入0.2ml 乙二醇溶液(0.16mol/L),室温(20℃左右)避光条件下下轻微搅拌30min。加入1mg的抗体溶液,混合均匀后装入透析袋中,置于CBS溶液中避光条件下透析6h(或4℃过夜)。从透析袋中取出反应液,加入50ul NaBH4溶液(5mg/ml),混匀置于4℃避光条件下2h。缓慢加入等体积(约1.2ml)的饱和硫酸铵溶液,混匀并置于4℃避光条件下30min,10000rpm离心10min去上清,以200ul的PBS重溶沉淀,然后置于PBS中透析12-18h,期间换液一次。 取出溶液并测量体积,加入等体积的甘油,充分混匀后于-20℃保存备用。
2. 配对抗体的筛选
用CB将包被抗体稀释到4μg/ml,以每孔100μl加入到酶标板孔中,4℃包被过夜。将酶标板拍干,每孔加入200μl封闭液(含1%BSA 的PBS),于37℃下封闭1-2h并拍干。将阳性血样用PBS稀释至2ng/ml,每孔加样100μl,以阴性血样为对照。37℃孵育1h后洗板3次,洗液为0.05%的PBST。用含1%BSA的洗液将酶标抗体稀释成1000倍的工作液,每孔加100μl,37℃孵育1h,然后洗板4次并拍干。每孔加入100μl TMB显色液,37℃孵育10min。每孔加50μl加入终止液,在酶标仪上用450nm读取OD值。结果如下。
三、配对抗体AMH-1/AMH-2的性能评估及相关参数
1. 配对抗体的特异性检测
按上述9的方法,对AMH-1/AMH-2配对的特异性进行检测,共使用25份阳性血清和25份阴性血清,以P/N≥2为阳性,结果如下。
2. 单克隆抗体的分型鉴定
使用抗体分型鉴定试剂盒SBA Clonotyping System-HRP(Southern Biotech, cat:5300-05),按说明书方法进行鉴定,结果如下图。
ELISA检测OD450计数。
配对抗体的可变区序列测定
将上述两个杂交瘤细胞株交由南京金斯瑞生物科技有限公司测定抗体可变区序列。
AMH-1重链可变区氨基酸序列
Gln Val Gln Leu Gln Gln Trp Gly Asp Leu Lys Val Pro Gly Ala
Ser Val Lys Gly Ser Cys Glu Ala Ser Gly Tyr Thr Phe Lys Ser Phe
Trp Ser Asn Trp Ile Lys Tyr Arg Pro Gly Gln Gly Trp Glu Trp Ile
Ala Arg Ser Gly Pro Gly Ser Tyr Ile Leu Gln Pro Asn Glu Val Phe
Lys Asp Asn Ala Thr Leu Thr Val Ala Thr Ser Ser Gys Thr Ala Tyr
Ile Gln Leu Val Asn Leu Ser Ser Glu Tyr Ser Ala Val His Phe Gys
Ala Ser Glu Arg Phe Tyr Tyr Gly His Val Gly Trp Phe Pro Ile Trp
Gly Gln Ile Thr Leu Val Gln Val Ser Ala Tyr Leu Asn Lys Gly Glu
Lys Trp Ile Ala Asn Thr Gly
AMH-1轻链可变区氨基酸序列
Ala Val Val Thr Ser Gln Ser Pro Ala Ile Leu Ser Val Gly Pro Gly
Glu Lys Val Thr Leu Thr Gly Arg Ala Ser Ser Leu Val Thr Tyr Met
His Trp Ala Gln Gln Lys Pro Gly Ser Ser Ser Gly Lys Trp Ile Leu
Ala Leu Thr Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
Gly Ser Gly Thr Ser Gly Ser Ala Thr Leu Ser Ser Met Glu Ala Glu
Asp Ala Ala Thr Tyr Leu Cys His Gln Trp Ser Ser Asn Pro Leu Gly
Phe Gly Ala Gly Thr Lys Ala Glu Ile Lys Ala Leu Gly Ala
AMH-2重链可变区氨基酸序列
Glu Val Met Leu Pro Glu Ser Gly Leu Gly Leu Val Lys Val Cys Gly
Val Leu Lys Leu Ser Cys Val Val Ser Gly Cys Thr Leu Ser Pro Tyr
Ala Met Ser Trp Val Leu Leu Thr Val Glu Arg Arg Leu Glu Trp Cys
Ala Val Ile Ser Cys Gly Val Ser Asn Leu Tyr Tyr Pro Asp Ser Val
Lys Trp Arg Phe Thr Ile Ser Arg Cys Asn Ala Lys Val Ile Leu Tyr
Leu Pro Met Val Ser Leu Arg Ser Asp Asp Thr Ala Cys Leu Tyr Cys
Val Leu Arg Gly Trp Asp Tyr Cys Pro Gln Gly Thr Val Val Thr Val
Ser Cys Val Leu Arg Ser Val Glu Phe Asn Lys Leu Thr Ser Ser Leu
Trp Met Asp Ile Gly
AMH-2轻链可变区氨基酸序列
Ile Glu Val Met Thr Gln Ser Pro Ser His Leu Thr Val Thr Ala Gly
Glu Lys Val Thr Met Asn Cys Lys Ser Ile Gln Ser Leu His Asn Glu
Gly His Gln Lys Glu Tyr Leu Ile His Phe Gln Gln Lys Thr Gly Gln
His Pro Lys Leu Leu Ile Glu Trp Ala Ser Thr Arg Glu Ser Gly Ile
Tyr Glu Arg Phe Ile Gly Ser His Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Asn Val Gln Ala Glu Ile Leu Ala Glu Tyr Tyr Cys His Thr
Asp Phe Ser Glu Pro Leu His Phe Gly Ala Ile Thr Lys Leu Glu Ile
Lys Asp Val Met Pro Leu Tyr Ile

Claims (2)

1.抗AMH单克隆抗体AMH-1和AMH-2,其抗体分型分别为IgG2b和IgG2b;
2.单克隆抗体AMH-1,其特征在于重链可变区的氨基酸序序列如SEQ ID NO:1所示,轻链可变区的氨基酸序列如SEQ ID NO:2所示 ;单克隆抗体AMH-2特征是重链可变区和轻链可变区的氨基酸序序列分别如SEQ ID NO:3和SEQ ID NO:4所示。
2.一种如权利要求3所述的单克隆抗体的应用,利用抗体AMH-1作为包被抗体,AMH-2作为标记抗体,建立的检测天然血清中AMH的DAS-ELISA方法。
CN201810382246.8A 2018-04-26 2018-04-26 一种抗amh单克隆抗体的制备及其应用 Pending CN110407937A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810382246.8A CN110407937A (zh) 2018-04-26 2018-04-26 一种抗amh单克隆抗体的制备及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810382246.8A CN110407937A (zh) 2018-04-26 2018-04-26 一种抗amh单克隆抗体的制备及其应用

Publications (1)

Publication Number Publication Date
CN110407937A true CN110407937A (zh) 2019-11-05

Family

ID=68345530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810382246.8A Pending CN110407937A (zh) 2018-04-26 2018-04-26 一种抗amh单克隆抗体的制备及其应用

Country Status (1)

Country Link
CN (1) CN110407937A (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111004326A (zh) * 2019-12-27 2020-04-14 苏州博方生物技术有限公司 一种抗amh单克隆抗体及其制备方法和应用
CN114478765A (zh) * 2020-11-12 2022-05-13 东莞市朋志生物科技有限公司 针对抗穆勒氏管激素的抗体以及检测抗穆勒氏管激素的试剂盒
WO2022100263A1 (zh) * 2020-11-12 2022-05-19 东莞市朋志生物科技有限公司 抗amh的抗体、检测amh的试剂和试剂盒
CN114891104A (zh) * 2022-06-09 2022-08-12 优睿赛思(武汉)生物科技有限公司 识别amh的单克隆抗体及其应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111004326A (zh) * 2019-12-27 2020-04-14 苏州博方生物技术有限公司 一种抗amh单克隆抗体及其制备方法和应用
CN114478765A (zh) * 2020-11-12 2022-05-13 东莞市朋志生物科技有限公司 针对抗穆勒氏管激素的抗体以及检测抗穆勒氏管激素的试剂盒
WO2022100263A1 (zh) * 2020-11-12 2022-05-19 东莞市朋志生物科技有限公司 抗amh的抗体、检测amh的试剂和试剂盒
WO2022100190A1 (zh) * 2020-11-12 2022-05-19 东莞市朋志生物科技有限公司 针对抗穆勒氏管激素的抗体以及检测抗穆勒氏管激素的试剂盒
CN114891104A (zh) * 2022-06-09 2022-08-12 优睿赛思(武汉)生物科技有限公司 识别amh的单克隆抗体及其应用
CN114891104B (zh) * 2022-06-09 2022-12-20 优睿赛思(武汉)生物科技有限公司 识别amh的单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
CN110407937A (zh) 一种抗amh单克隆抗体的制备及其应用
CN113138276B (zh) 用于检测HBcAg的方法及抗体
CN111378043A (zh) 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN105695419A (zh) 杂交瘤细胞株4C9及其产生的抗His标签蛋白单克隆抗体
CN106008720A (zh) 一种辣根过氧化物酶与抗体片段的融合蛋白及应用
CN107523552A (zh) 分泌抗amh单克隆抗体的杂交瘤细胞株、抗amh单克隆抗体及应用
CN101701039A (zh) Fmu-epcam-2a9单克隆抗体的轻链和重链可变区
CN108456252B (zh) 高特异性的抗兔IgG天然构象单克隆抗体
EP0142345A2 (en) Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies
US11906520B2 (en) Composition and methods for detecting cancer
CN115947854B (zh) 抗人cd40蛋白单克隆抗体、制备方法及其应用
JPH05503849A (ja) Tshのヒト受容体及びこの受容体をコードする配列
US5648469A (en) Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
CN110283247A (zh) 抑制素b单克隆抗体的制备方法
JP4059404B2 (ja) 甲状腺機能を刺激する活性を持つ抗体
CN112795543B (zh) 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
CN108623684B (zh) 一种识别贝伐珠单抗的单克隆抗体及其应用
CN116761889A (zh) 抗原结合蛋白及其用途
CN112730854A (zh) 一种排卵检测试纸条及检测方法
CN108623688B (zh) 一种中和贝伐珠单抗的单克隆抗体及其应用
CN114957468A (zh) 一种抗Siglec15抗体及其用途
CN114891104B (zh) 识别amh的单克隆抗体及其应用
CN109655619A (zh) 一种检测鸡白细胞介素12含量的方法及其专用试剂盒
KR20200067522A (ko) 신규 항체 및 이의 용도
CN110133278A (zh) 一种用于检测人vegf蛋白表达水平的体外试剂盒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191105